Health policy

The audit includes a review of the process safety information, inspection of the physical facilities, and interviews with all levels of plant personnel. Using the procedures and checklist, the team systematically analyzes compliance with the PSM Rule and any other relevant corporate policies. The training program is reviewed for adequacy of content, frequency and effectiveness of training. Interviews determine employee knowledge and awareness ofthe safety procedures, duties, rules, and emergency response assignments. The team identifies deficiencies in the application of safety and health policies, procedures, and work authorization practices to determine live actions. 

EuroQol Group (1990). EuroQol—a new facility for the measuremenr of healrh-relared quality of life. Health Policy 199—208. 

FFealey AT, Ghisholm DFF (1999). Willingness-to-pay methods in mental health care. /Ment Health Policy Econ 2, 55—8. 

Johannesson M (1995). A note on the depreciation of the societal perspective in economic evaluation of health care. Health Policy 33, 59-66. 

In the wider medicopolitical arena, the health cost of the anxiety disorders more than justifies pleas to accord their treatment greater prominence in health policy and research funding (Rupp et al, 1998). 

Alzheimer s disease in the United Kingdom. Burden of disease and future care. Health Policy Review paper 12. Health Policy Unit, Imperial College School of Medicine,... 

Martin Knapp is Professor of Health Economics and Director of the Centre for the Economics of Mental Health at the Institute of Psychiatry, and Professor of Social Policy at the London School of Economics and Political Science, London, UK. Much of his work focuses on the economic aspects of mental health services and health policy. He is also actively involved in work looking at economic aspects of long-term care for older people. 

Walt G. Health policy an introduction to process and power. London, Zed Books, 1994. 

Center for Health Policy Research and Development, National Health Research Institutes, Taiwan... 

PJ Feldstein. Health Policy Issues An Economic Perspective on Health Reform. 2nd ed. Chicago Health Administration Press/AUPHA Press, 1999, pp. 193-207. 

Brundtland, G. H. Winning the war against AIDS, tuberculosis, and malaria. Harvard Health Policy Rev. 2002,3(2). 

Garattini, L. and F. Tediosi (2000), A comparative analysis of generics markets in five European countries , Health Policy, 51, 149-62. 

Zanunit-Lucia, J. and R. Dasgupta (1995), Reference pricing the European experience , Health Policy Review, St. Mary s Hospital Medical School paper no 10, London. 

Lopez-Casanovas, G. and J. Puig-Junoy (2000), Review of the literature on reference pricing , Health Policy, 54, 87-123. 

Drummond, M., B. Jonsson and F. Rutten (1997), The role of economics evaluation in the pricing and reimbursement of medicines , Health Policy, 40, 199-215. 

Giuliani, G., G. Selke and L. Garattini (1998), The German experience in reference pricing , Health Policy, 44, 73-85. 

However, these results are not applicable to compulsory pubhc insurance, nor to National Health Systems. The most notable differences between drag co-payment in an insurance market and in a National Health System or compulsory public insurance environment lie in their voluntariness or otherwise (users ability to choose their coverage) and the ultimate financing of the services (risk-adjusted premiums as opposed to taxes or social insurance contributions adjusted according to economic capacity). Hence, in compulsory public insurance systems, co-payment regulation is used not only as a health policy instrument but also as one of redistribution of income. 

Lundberg, L. et al. (1998), Effects of user charges on the use of prescription medicines in different socio-economic groups , Health Policy, 44, 123-34. 

Stuart, B. et al. (2000), Issues in prescription drug coverage, pricing, utilization and spending what we know and need to know , report prepared for US Department of Health and Human Services, Office of the Assistant Secretary for Policy and Evaluation, Office of Health Policy, Washington, DC, February, accessed at http //www.aspe.hhs.gov/health/reports/drugstudy/appa.htm. 

This chapter on prescriber incentives brings together various midpoints, all of them difficult to find. One of these midpoints concerns incentives (if there is one distinguishing feature of health care organizations it is the advisability of moderating the power of incentives in order to stop financial considerations from short-circuiting clinical considerations) another concerns the balance between health policy issues and industrial policy ones and a third concerns the influences exerted on prescription by the market, the state and clinical standards (the combination of financial and non-financial incentives). 

Abel-Smith, B. and E. Mossialos (1994), Cost containment and health care reform a study of the European Union , Health Policy, 28, 89-132. 

It seems likely that in the future we will need to tackle health problems from an angle that has more in common with the idea of a social insurance system. System for a better interlocking of ultimate objectives and health care services between public and private actors, and between different public actors, all politically legitimated throughout the territory, and for their better coordination, crucial for the success of ary health policy. Insurance because of the inescapable nature of the idea of specifying levels of health care coverage and... 

Reports of racial disparities in medical care and health status in the United States are common. The United States government has targeted the elimination of racial disparities in health status as a national priority in health policy [18]. Examples of racial disparities include differences in the aggressiveness of treatment ordered for white patients and black patients with cancer [19] and heart disease... 

Health Policy and Law University of Louisville School of Medicine... 

Matherlee K. The Public Stake in Biomedical Research a Policy Perspective. National Health Policy Forum, November 1999, USA. http /www.cdc.gov/nih ... 

Herbert F. Boehl Chair of Law and Medicine Director, Institute for Bioethics, Health Policy and Law University of Louisville, School of Medicine Louisville, KY... 

At the Institute for Bioethics, Health Policy and Law at the University of Louisville, my colleague Gabriela Alcalde helped me in conceptualizing the key issues and also took the lead in drafting two articles we coauthored on the topic. Dr. Mary Anderlik coauthored a paper with me on genetic research in which pharmacogenomics was a key element. Dr. Carl Hornung of the Department of Medicine contributed indispensable data analysis on the survey and coauthored Chapter 1 of this volume. 

Larry I. Palmer, LL.B., Institute for Bioethics, Health Policy and Law, University of Louisville School of Medicine, Louisville, KY C.E. Reeder, Ph.D., Center for Outcomes Research and Evaluation, College of Pharmacy, University of South Carolina, Columbia, SC John A. Robertson, J.D., School of Law, University of Texas at Austin, Austin, TX Mark A. Rothstein, J.D., Institute for Bioethics, Health Policy and Law, University of Louisville School of Medicine, Louisville, KY... 

Our survey consisted of randomly dialed telephone interviews of 1796 individuals across the country performed by Telesurveys Research Associates of Houston, Texas, under contract with the Institute for Bioethics, Health Policy and Law of the University of Louisville School of Medicine. The research was funded by the following three Institutes of the National Institutes of Health (NIH) National Institute of General Medical Sciences (lead institute),... 

---